Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452787 · ClinicalTrials.gov registry record
Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction
A clinical trial of Body Mass Index, sponsored by Tufts University.
- Completed
- Registry status
- 602
- Enrollment target
- 1
- Study location
NCT03452787: Completed study of Body Mass Index, sponsored by Tufts University.
NCT03452787 is a study of Body Mass Index that has completed, run by Tufts University. The registered enrollment target is 602 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452787, a study of Body Mass Index, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- 602 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity is driven by genetic and environmental factors. Among the latter, diet is a most important one. The investigators refer to these combinations of genetic and dietary factors as 'gene-diet interactions.' Higher consumption of saturated fats (found mostly in foods of animal origin) has been associated with higher weight in people who were homozygotes for the minor allele at a genetic variant known as APOA2 -265 T\>C (rs5082). In the current study, the investigators will seek to gain an understanding of the biological mechanisms driving this interaction. The investigators will select participants in three cohorts according to this genetic factor and conduct a series of molecular analyses (epigenetics, transcriptomics, and metabolomics). The analyses will identify epigenetic marks that are associated with saturated fat intake exclusively in subjects who carry this genetic factor. Moreover, the investigators will examine the association between epigenetic status and genotype at APOA2 and mRNA expression of the gene, and concentrations of metabolites in the blood. This study will increase the understanding of how genetics and diet act together to promote weight gain, and may eventually have implications for dietary recommendations that make use of genetic information.
Primary Outcome
BMI calculated based on weight (kg) and height (meters) information from each participant using the equation BMI=kg/m2
Conditions Studied
Interventions
- OTHER None, cohort studies
Study Locations (1)
Massachusetts
- JM-USDA-HNRCA at Tufts University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2017-12-31 |
What the finished NCT03452787 record still lists
NCT03452787 is an observational study that tracks outcomes without assigning an intervention. The registered 602 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Body Mass Index appearing as the primary indexed condition, and to 1 intervention - of which None, cohort studies is the first listed.
NCT03452787 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03452787 about?
NCT03452787 is a clinical study titled "Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction". Obesity is driven by genetic and environmental factors. Among the latter, diet is a most important one. The investigators refer to these combinations of genetic and dietary factors as 'gene-diet interactions.' Higher consumption of saturated fats (found mostly in foods of animal origin) has been ass...
What is the current status of trial NCT03452787?
This trial is currently completed. The enrollment target is 602 participants. The study started on 2017-01-01. Estimated completion is 2017-12-31.
What conditions does trial NCT03452787 study?
This clinical trial studies the following conditions: Body Mass Index.
What interventions are being tested in trial NCT03452787?
The interventions under investigation include: None, cohort studies (OTHER).
Who is sponsoring clinical trial NCT03452787?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03452787 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Body Mass Index
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI